FDA WARNING_LETTER - Miach Orthopaedics - April 23, 2025

**FDA Warning Letter Summary**

**Company Name:** [Company Name]

**Inspection Dates:** March 31, 2025 - April 23, 2025

**Main Violations/Issues:** 1. **Quality System Regulation Violations:** The FDA inspection revealed that the manufacturing processes for the Bridge-Enhanced ACL Restoration (BEAR) Implant were not in compliance with the Quality System regulation (21 CFR Part 820). Specifically, the firm failed to establish adequate procedures for monitoring and controlling process parameters for validated processes, notably in the sterility assurance level of their E-Beam sterilization process.

2. **Nonconforming Product Control:** The company did not implement procedures to control products that do not meet specified requirements. This includes failing to generate nonconformance reports for BEAR Implant devices that exceeded bioburden limits.

3. **Design Requirements Procedures:** The firm did not maintain procedures to ensure design requirements are appropriate and address the device"s intended use, including user and patient needs.

**Regulatory Framework:** The violations fall under the Federal Food, Drug, and Cosmetic Act, specifically sections 201(h) and 501(h), and the Quality System regulation (21 CFR Part 820).

**Required Actions:** - Re-implement bioburden monitoring procedures for both facultative and strict anaerobic microorganisms. - Review and potentially revise procedures for bioburden monitoring to align with contract manufacturing standards. - Establish new procedures for nonconforming products and revise existing ones to ensure proper evaluation and disposition of devices with bioburden excursions. - Provide timelines for corrective actions and continue to update the FDA on progress, including supporting evidence.

The FDA has requested a detailed response addressing these deficiencies and expects continuous updates on corrective measures.